Recent News

ASCO 2021: Adjuvant Capecitabine Versus Platinum-Based Chemotherapy for Residual Triple-Negative Breast Cancer

ASCO 2021: COVID-19 Outcomes and Breast Cancer by Racial/Ethnic Group

Androgen Receptor–Targeting Agent Under Study in Metastatic Disease

ASCO 2021: Survival Outcomes With De-escalated Neoadjuvant Treatment of Early Breast Cancer

ASCO 2021: OlympiA Trial of Adjuvant Olaparib After Chemotherapy for Early-Stage Breast Cancer

ESMO Breast 2021: Atezolizumab Plus Carboplatin for Metastatic Invasive Lobular Cancer

ESMO Breast 2021: Distinct Gene Signatures Associated With Pathologic Complete Response

ESMO Breast 2021: Does Clinical Benefit From Endocrine Therapy Differ by Risk Group?

Adding Oral Alisertib to Weekly Paclitaxel for Metastatic Breast Cancer

ESMO Breast 2021: Clinical Role of RAD51 Testing in Triple-Negative Breast Cancer

ESMO Breast 2021: Safety Outcomes With Abemaciclib Plus Endocrine Therapy in Early Breast Cancer

Eribulin and Pembrolizumab Combination in Triple-Negative Breast Cancer

ASBrS 2021: Can Medicaid Expansion Improve Disparities in Breast Reconstruction?

APHINITY Trial Update: Adjuvant Pertuzumab-Based Therapy in Early HER2-Positive Breast Cancer

Treadmill and T Cells: Can Exercise Enhance Immune Responses in Breast Cancer?

Can Healthy Plant-Based Diets Decrease the Risk of Breast Cancer?

Predicting Response to Combination Therapies for Breast Cancer Brain Metastases

AACR 2021: Can Gut Microbiota Influence Treatment Response in Metastatic Breast Cancer

Distant Lymph Node Metastases From Breast Cancer: A Regional Disease?

AACR 2021: Using ctDNA Changes to Predict Response to Palbociclib-Based Therapy for Breast Cancer

AACR 2021: Talazoparib/Carboplatin Under Study in Triple-Negative Breast Cancer

Fixed-Dose Pertuzumab-Based Regimen Under Study in FeDeriCa Trial

Could Regularly Drinking Sugar-Sweetened Soda Be Linked to Breast Cancer Mortality?

Is Surveillance Mammography Necessary in Older Breast Cancer Survivors?

AACR 2021: Neratinib Plus Fulvestrant for HER2-Mutant Metastatic Breast Cancer

FDA Brief: Cryoablation Technology Receives Breakthrough Device Designation in Breast Cancer

Are Type 2 Diabetes and Metformin Use Associated With Breast Cancer Risk?

Sacituzumab Govitecan-hziy Receives Regular FDA Approval for Triple-Negative Breast Cancer

FDA Grants Two New Breakthrough Device Designations for MRD Testing

Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel

KEYNOTE-355 Update on Pembrolizumab in Triple-Negative Breast Cancer

Risk of Breast Cancer in Common Drugs for Diabetes and Obesity

Endocrine Therapy for Men With Breast Cancer: Estradiol Levels, Sexual Function, and Quality of Life

Company Announces Discontinuation of Development of Oral Taxane Tesetaxel

Miami Breast Cancer Conference 2021: DESTINY-Breast01 Trial Update on Trastuzumab Deruxtecan-nxki

Miami Breast Cancer Conference 2021: Neratinib-Based Regimens for CNS Metastases

Are Most Women Who Forgo Reconstruction After Mastectomy Satisfied With the Results?

Miami Breast Cancer Conference 2021: Tolerability of Capecitabine in U.S. Patients With Triple-Negative Breast Cancer

Miami Breast Cancer Conference 2021: Comparing Radiolabeled Mapping Agents in Identifying Sentinel Lymph Nodes

Margetuximab-cmkb Versus Trastuzumab in ERBB2-Positive Advanced Breast Cancer

Miami Breast Cancer Conference 2021: Neoadjuvant Chemotherapy in Minority Groups

PD-L1 mRNA Expression and Treatment Response in Triple-Negative Breast Cancer

FDA Flags Safety Concerns for Oral Paclitaxel Plus Encequidar in Treatment of Breast Cancer

ASCO Guideline: Focus on Optimal Neoadjuvant Therapy for Breast Cancer

Can Androgen Receptor Agonists Improve Outcomes in Estrogen Receptor–Positive Breast Cancer?

Neoadjuvant Regimens Compared in Advanced Operable Breast Cancer

COVID-19 and Breast Cancer: Protective Role for Antiestrogen Therapies?

MONALEESA-7 Update: Ribociclib Plus Endocrine Therapy for Advanced Breast Cancer

Phase II Basket Trial of Dual HER2-Targeted Therapy in Metastatic Breast Cancer

World Health Organization Reports Breast Cancer Now the Most Common Type of Cancer Worldwide

Ribociclib/Letrozole in UK Subgroup of Phase IIIb Trial of Advanced Breast Cancer

Survival Outcomes in Early HER2-Positive Breast Cancer: Focus on Body Mass Index

Outcomes With Chemotherapy May Differ by Menopausal Status: Report From RxPONDER

Addition of Entinostat to Endocrine Therapy for Advanced Breast Cancer

Are Statins Cardioprotective in Patients Treated With Chemotherapy for Early Breast Cancer?

Adding a Tumor Bed Boost to Whole-Breast Irradiation for Ductal Carcinoma in Situ

Androgen Receptor Modulator in ER-Positive/AR-Positive Breast Cancer

Are Individuals With Multiple Sclerosis at Higher Risk of Developing Breast Cancer?

IPATunity130 Trial of Ipatasertib Plus Paclitaxel for Advanced Triple-Negative Breast Cancer

Oral Contraceptives and Risk of Breast Cancer

Tesetaxel Plus Reduced-Dose Capecitabine in Metastatic Breast Cancer

FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers

Shortened Course of Radiotherapy for Breast Cancer After Surgery

Enumeration of CTCs in Predicting Therapeutic Outcomes in Metastatic Breast Cancer

Preclinical Trial Explores Anti–PD-1 Strategies for Triple-Negative Breast Cancer

Recognizing Adverse Symptoms in Patients Undergoing Breast Radiotherapy

Trop-2 Expression and Sacituzumab Govitecan in Triple-Negative Breast Cancer

SABCS 2020: Pembrolizumab Plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

Comparison of Number of Fractions of Accelerated Partial Breast Irradiation

Margetuximab-cmkb in Combination With Chemotherapy Approved by FDA for Metastatic Breast Cancer